Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.

[1]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[2]  R. Allman,et al.  Baseline characteristics, quality of care, and outcomes of younger and older Medicare beneficiaries hospitalized with heart failure: findings from the Alabama Heart Failure Project. , 2012, International journal of cardiology.

[3]  R. Bonow,et al.  Rheumatic heart disease and risk of incident heart failure among community-dwelling older adults: A prospective cohort study , 2012, Annals of medicine.

[4]  R. Allman,et al.  A propensity-matched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in heart failure patients age ≥ 65 years. , 2011, The American journal of cardiology.

[5]  R. Bonow,et al.  Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure. , 2011, International journal of cardiology.

[6]  Peter Jüni,et al.  An overview of the objectives of and the approaches to propensity score analyses. , 2011, European heart journal.

[7]  G. Fonarow,et al.  Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. , 2011, The American journal of cardiology.

[8]  I. Piña,et al.  Gender-related dissociation in outcomes in chronic heart failure: reduced mortality but similar hospitalization in women. , 2011, International journal of cardiology.

[9]  Ali Ahmed,et al.  Evidence of a "heart failure belt" in the southeastern United States. , 2011, The American journal of cardiology.

[10]  G. Filippatos,et al.  Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. , 2011, European heart journal.

[11]  G. Fonarow,et al.  Warfarin use and outcomes in patients with advanced chronic systolic heart failure without atrial fibrillation, prior thromboembolic events, or prosthetic valves. , 2011, The American journal of cardiology.

[12]  G. Bakris,et al.  Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. , 2010, International journal of cardiology.

[13]  C. O'connor,et al.  Comparison of Medical Therapy Dosing in Outpatients Cared for in Cardiology Practices With Heart Failure and Reduced Ejection Fraction With and Without Device Therapy: Report From IMPROVE HF , 2010, Circulation. Heart failure.

[14]  G. Filippatos,et al.  Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. , 2010, International journal of cardiology.

[15]  Ali Ahmed,et al.  Incident coronary revascularization and subsequent mortality in chronic heart failure: a propensity-matched study. , 2010, International journal of cardiology.

[16]  G. Bakris,et al.  Hypokalemia and Outcomes in Patients With Chronic Heart Failure and Chronic Kidney Disease: Findings From Propensity-Matched Studies , 2010, Circulation. Heart failure.

[17]  G. Filippatos,et al.  Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. , 2010, Journal of the American Society of Hypertension : JASH.

[18]  R. Campbell,et al.  Epidemiology of chronic kidney disease in heart failure. , 2008, Heart failure clinics.

[19]  Peter C Austin,et al.  Report Card on Propensity-Score Matching in the Cardiology Literature From 2004 to 2006: A Systematic Review , 2008, Circulation. Cardiovascular quality and outcomes.

[20]  Ali Ahmed,et al.  Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. , 2007, The American journal of cardiology.

[21]  M. Rich,et al.  Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. , 2006, Journal of Cardiac Failure.

[22]  M. Gheorghiade,et al.  Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. , 2006, European heart journal.

[23]  Di Xie,et al.  Efficacy and safety of benazepril for advanced chronic renal insufficiency. , 2006, The New England journal of medicine.

[24]  L. Hebert.  Optimizing ACE-inhibitor therapy for chronic kidney disease. , 2006, The New England journal of medicine.

[25]  C. O'connor,et al.  Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. , 2005, Journal of the American College of Cardiology.

[26]  R. Centor,et al.  A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications. , 2005, American heart journal.

[27]  P. Rothwell.  Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.

[28]  M. Tonelli,et al.  The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. , 2004, Journal of the American College of Cardiology.

[29]  J. Butler,et al.  Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. , 2003, Journal of the American College of Cardiology.

[30]  D. Rubin.  Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation , 2001, Health Services and Outcomes Research Methodology.

[31]  S. Jencks,et al.  Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. , 2003, JAMA.

[32]  R. Sims,et al.  Survival Benefits of Angiotensin‐Converting Enzyme Inhibitors in Older Heart Failure Patients with Perceived Contraindications , 2002, Journal of the American Geriatrics Society.

[33]  A. Ahmed,et al.  Use of Angiotensin‐Converting Enzyme Inhibitors in Patients with Heart Failure and Renal Insufficiency: How Concerned Should We Be by the Rise in Serum Creatinine? , 2002, Journal of the American Geriatrics Society.

[34]  E. Braunwald,et al.  Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials. , 2002, JAMA.

[35]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  R. Bonow,et al.  Introduction and overview: beta-blocker therapy in the management of chronic heart failure. , 2001, American Journal of Medicine.

[38]  M. Mcclellan,et al.  Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. , 2000, Archives of internal medicine.

[39]  G. Bakris,et al.  Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? , 2000, Archives of internal medicine.

[40]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[41]  R. Collins,et al.  Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. , 1999, American journal of epidemiology.

[42]  C. O'connor,et al.  Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. , 1997, The American journal of cardiology.

[43]  T. Cox,et al.  Uveitis in the southeastern United States. , 1997, Current eye research.

[44]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[45]  S. Yusuf,et al.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. , 1995, JAMA.

[46]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[47]  M. Pfeffer,et al.  Angiotensin converting enzyme inhibition and ventricular remodeling in heart failure. , 1988, The American journal of medicine.

[48]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[49]  J. Cohn.  Physiologic basis of vasodilator therapy for heart failure. , 1981, The American journal of medicine.

[50]  N. Hollenberg,et al.  Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. , 1980, The New England journal of medicine.